Outcomes with tafasitamab + lenalidomide for LBCL pre- or post-CAR T-cell therapy

For patients with R/R LBCL who received tafasitamab + lenalidomide after progression with anti-CD19 CAR T-cell therapy, the median PFS, OS, and DOR after progression were 3, 4.7, and 8.1 months, respectively. 

Patients who received tafasitamab + lenalidomide for relapse >6 months after CAR T-cell infusion had better outcomes compared with those who received tafasitamab + lenalidomide <6 months after CAR T-cell infusion; median PFS was 5.6 vs 2 months, respectively (p = 0.0138), and median OS was not reached vs 3.8 months, respectively (p = 0.0034).

The efficacy of tafasitamab + lenalidomide post-CAR T-cell therapy was comparable to other salvage therapies; there was no significant difference in PFS and OS when comparing tafasitamab + lenalidomide to other treatment options or lenalidomide alone.

The number of patients who received tafasitamab + lenalidomide before CAR T-cell therapy was too low to determine its impact on post-CAR T-cell treatment outcomes.